<DOC>
	<DOC>NCT00718341</DOC>
	<brief_summary>This study will evaluate the safety, tolerability and efficacy of multiple doses of AFQ056 in patients with Fragile X Syndrome. The dose range will be 50 to 150 mg b.i.d. The primary read-out of efficacy is reduction in Aberrant-Behavior Checklist score.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male, nonsmoking patients between 18 and 35 years of age (both inclusive). Patients with fmr1 full mutation (&gt; 200 CGG repeats) Patients with a Clinical Global Impression Severity Score (CGIS) of &gt; 4 (moderately ill) Patients with a score of &gt;20 in the ABCC scale (at screening) Patients with a mental age of â‰¥ 48 months as measured by the StanfordBinet test Patients with DSMIV diagnosis of schizophrenia, history and/or presence of psychosis, confusional states and/or repeated hallucinations. Patients with a history of seizures in the past 5 years without any therapeutic treatment controlling the disorders. Patients under stable anticonvulsant therapies that experienced seizures in the 2 years prior to randomization Patients with ECG abnormalities, autonomic dysfunctions, bronchospastic diseases, drug or atopic allergy Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs Patients using (or have used within four weeks before randomization) concomitant medications that are potent inhibitors of CYP3A4 (e.g., ketoconazole, ritonavir, etc.) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Fragile X Syndrome, adults, efficacy</keyword>
</DOC>